SUMMARY Glyceryl trinitrate was previously said to be contraindicated in patients with acute myocardial infarction. Its intravenous administration during acute infarction, however, was associated with a beneficial effect as determined by ST segment mapping. Most recently in a selected group of patients with acute infarction and abnormal haemodynamics, intravenous glyceryl trinitrate was shown to reduce infarct size estimated by enzymes. The present study was performed to verify the safety of intravenous glyceryl trinitrate in patients with infarction under conventional clinical conditions without invasive monitoring and to determine its effect on infarct size in a prospective randomised trial involving 85 patients with infarction (43 treated and 42 control). Treated patients received glyceryl trinitrate within 10 hours of the onset of symptoms (mean 6.0 hours), and the dose was titrated to preset limits for changes in heart rate and blood pressure. In patients with inferior infarction, infarct size estimated by enzymes in the treated was only 122+ 1-8 versus 19*1+3-6 CK gram equivalents per metre squared in the placebo group. A similar but statistically insignificant trend was observed for subendocardial infarction but no difference was observed for anterior infarction. Ventricular arrhythmias determined from 24 hour tapes were more frequent in treated patients though this was not statistically significant. Lignocaine requirements in treated and control (1692±+250 vs 1512+232 mg/24 h) were similar, as were the requirements for morphine (1 1 4±+18 vs 12.2+2.2 mg/24 h). Results indicate that intravenous glyceryl trinitrate can be administered safely during evolving infarction without invasive monitoring and reduces infarct size in patients with inferior infarction.
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Glyceryl trinitrate has been used for treatment of chest pain syndromes since 1879' and has since played a major role in the management of patients with angina pectoris. Because, however, sublingual glyceryl trinitrate sometimes induces hypotension and tachycardia in patients with evolving infarction2 3 it was thought to be contraindicated in this setting. 4 In the 1970s intravenous glyceryl trinitrate was used instead, based in part on results of studies in experimental animals56 suggesting a beneficial effect on ischaemic myocardium. The use of an intravenous rather than a sublingual or oral preparation made it possible to titrate the dosage to avoid deleterious This study was supported in part by a SCOR in Ischemic Heart Disease, National
Institutes of Health grant.
Accepted for publication 26 November 1982 effects on systemic arterial blood pressure. Preliminary studies in 12 patients with acute myocardial infarction showed that glyceryl trinitrate infused for 30 minutes was associated with improved haemodynamics and more rapid regression of ST segment elevation. 7 Subsequently, the same group observed similar results with administration of glyceryl trinitrate for up to three hours in 30 patients with acute infarction.8 In selected patients with acute myocardial infarction and abnorml haemodynamics, intravenous glyceryl trinitrate was recently found to improve haemodynamics and reduce infarct size estimated with enzymes.9 It now appears that afterload reduction in the setting of cardiac failure with or without infarction impairs cardiac perfusion. Reduction of afterload and preload with intravenous glyceryl trinitrate may also reduce infarct size in patients with cardiac failure.9 The safety and efficacy of intravenous glyceryl trinitrate in patients with incomplete infarction, however, have not been assessed.
This study was performed with two major objectives. First, to verify the safety of administration of intravenous glyceryl trinitrate to patients with infarction under conventional, clinical conditions without resort to invasive monitoring; and second, to determine prospectively its effect on infarct size in a randomised trial, with prior categorisation of patients according to the site of infarction. The latter we felt might be important since the heart rate and haemodynamic responses to inferior infarction are different and concomitant involvement of the right ventricle is unique.
Subjects and methods

PATIENT POPULATION
Patients were studied prospectively and randomised to the placebo or treated group. The study involved 114 patients who were admitted to the Barnes Hospital coronary care unit with suspected acute myocardial infarction. Criteria for entry were: (1) chest pain suspected to be of cardiac origin; (2) ,ug/ml. The solution was passed through a miulipore filter before testing for verification of sterility and lack of pyrogenicity. To avoid impaired potency, a fresh solution was prepared every two weeks. After enrolment of a patient in the study, a randomisation envelope was selected which indicated the group to which the patients should be assigned, that is glyceryl trinitrate or placebo. Treatment with intravenous glyceryl trinitrate was initiated as soon as possible after admission of the patient to the coronary care unit at a dose of 10 ug/min and increased by 10 ,g/min increments after 10 minute intervals until the desired end-point was achieved (see below). The glyceryl trinitrate solution was kept in a glass container and infused through plastic tubing as short as possible to minimise adsorption. The desired end-point consisted of either a 10%/o reduction in systolic blood pressure, attainment of a systolic blood pressure of 95 mmHg, or attainment of a maximum dose of 200 jug/min, whichever occurred first. The infusion was reduced if systolic arterial pressure decreased to 90 mmHg or less or if the heart rate increased by more than 20 beats/minute or slowed to less than 50 beats/minute. During initial titration heart rate and blood pressure were monitored every five minutes and hourly thereafter. Hypotension was treated by stopping the infusion, raising the legs, and administering fluids intravenously, and if concomitant bradycardia occurred, atropine was administered. Infusion of glyceryl trinitrate was continued for 24 (Table 4) . MORPHINE 
REQUIREMENTFS
Morphine requirements during the first 24 hours were similar in treated and control patients as shown in Fig. 3 , with a mean dose of 114±+1-8 mg in treated and 12-2±2 2 mg in controls. Patients in the treated group received an average of 1692+±250 mg lignocaine during the initial 24 hours, similar to requirements in controls of 1512±232 mg (Fig. 4) . Though ventricular extrasystoles were more frequent in the treated group than in the controls, the difference was not significant. Among treated and control patients with inferior infarction, the frequency of ventricular extrasystoles was 225±86 and 130±42 (p=NS). Corresponding values for patients with anterior infarction were 204±+86 and 123±+76 (p=NS), and for subendocardial infarction they were 153+75 ventricular extrasystoles/24 hours and 124±13 (p=NS) in control patients. Similar trends, again not significant, were noted for couplets and ventricular tachycardia. Treated patients had 5*07± 1 episodes of couplets or ventricular tachycardia over the 24 hour period compared with 2-43±0-8 episodes per 24 hours in the control patients (p=NS).
Discussion
Among the 114 randomised patients, 85 were subsequently documented to have acute myocardial infarction, 43 of whom were treated with intravenous glyceryl trinitrate and 42 with placebo. Six treated patients developed transient hypotension, which was reversed rapidly with no overt clinical sequelae. Infarct size among patients with inferior infarction was significantly reduced by glyceryl trinitrate and was 36% less than infarct size in controls. Similar, but non-significant differences were observed in patients with subendocardial infarction. Enzymatic estimates of infarct size in conventionally managed patients correlate closely with the severity of ventricular dysfunction,'6 17 ventricular arrhythmias,'8 early'9-23 and long-term mortality,2' 24 tomographic estimates,25 and morphological estimates of infarct size determined at necropsy in patients who succumb.23 In experimental animals, enzymatic estimates correlate closely with morphological estimates despite increased coronary flow induced by agents such as verapamil26 or nifedipine.27 Nevertheless, data in experimental animals28 29 suggest that the rate of release of CK into the circulation may be somewhat flow limited with sustained coronary occlusion. We have previously shown in dogs with experimental infarction that intravenous glyceryl trinitrate does not influence the CK disappearance rate or release ratio and that estimates of infarct size based on CK release correlated closely (r=0.85) with morphological estimates of infarct size. ) In this experimental preparation, however, infarction was produced by sustained coronary ligation. In patients with inferior infarction in whom we showed a beneficial effect in the present study, coronary flow may have been increased because of increased collateral flow or possibly relief of coronary arterial spasm. If, in fact, this were the case, greater washout of CK may have occurred as a result of increased flow. Thus, infarct size in treated patients would be overestimated, thereby masking, in part, beneficial effects. Accordingly, we may have underestimated the magnitude of salvage.
Glyceryl trinitrate is a potent agent for reversing cardiac ischaemia and relieving associated chest pain. The lack of apparent relief of chest pain (judging from morphine requirements) seen in patients with infarction who were given intravenous glyceryl trinitrate compared with those given placebo may be the result of the nature of pain associated with irreversible as opposed to reversible injury observed in patients with angina.
In contrast to results of a previous study3' suggesting that sublingual glyceryl trinitrate may reduce ventricular arrhythmias, the number of ventricular extrasystoles and complex arrhythmias was more frequent in treated patients in our study, though the differences were not statistically significant. Nevertheless, one should be aware of the potential for increased arrhythmias with administration of glyceryl trinitrate and take the necessary precautions. The increased ventricular extrasystolic activity might affect the magnitude and/or duration of altered haemodynamics and possible arrhythmogenicity caused by regional or subendocardial increase in coronary flow analogous to reperfusion-induced arrhythmias. The impact of glyceryl trinitrate on ventricular extrasystoles was independent of the effect on infarct size.
SIDE EFFECTS OF GLYCERYL TRINIT'RATE
The incidence of tachycardia as a factor limiting the dose of glyceryl trinitrate was low in our series (20%) in keeping with the results of others.7 9 In the previous clinical studies in which intravenous glyceryl trinitrate was administered to patients with acute myocardial infarction, tachycardia was uncommon. Thus, intravenous glyceryl trinitrate can be administered safely if blood pressure and heart rate are monitored frequently, and if dose is titrated according to preset limits for each.
COMPARISON OF RESULTS OF OTHER STUDIES
In the study by Bussman et al. 9 intravenous glyceryl trinitrate was administered to 31 patients with acute infarction with raised left ventricular filling pressure, 18 of whom had anterior infarction. The end-point assessed was infarct size estimated from plasma CK.
In keeping with our results, a beneficial effect on infarct size was observed. The population included patients with anterior and inferior infarction, but 4Jaffe, Geltman, Tiefenbrunn, Ambos, Strauss, Sobel, Roberts results were not analysed separately for inferior infarction; thus it is not possible to determine if the beneficial effect of glyceryl trinitrate was restricted to patients with inferior infarction as in our study. Borer et al.32 showed that glyceryl trinitrate given alone is beneficial only in patients with cardiac failure. In a study by Flaherty et al.,7 however, intravenous glyceryl trinitrate administered for 30 minutes to 12 patients with or without failure led to a greater decline in ST segment elevation than that seen in controls. Similar changes in ST segments were observed by the same group in a later study involving 15 Decreased myocardial oxygen demand seems less likely to account for the beneficial effects observed, since reduction in blood pressure of even greater magnitude in experimental animals does not consistently decrease infarct size.3" Since inferior infarction, however, is often associated with some infarction of the right ventricle,52 the beneficial effects on overall (right plus left) enzymatically estimated infarct size may be mediated in part through favourable effects of glyceryl trinitrate on right ventricular loading conditions and oxygen requirements. Since this investigation did not attempt to evaluate the mechanism of action of glyceryl trinitrate, it is difficult to assess why patients with anterior infarction did not show similar beneficial effects. It should be emphasised, however, that the apparent lack of effect may be a function of small sample size. Alternatively, it is possible that the exclusion of patients with hypertension, tachycardia, hypotension, and cardiogenic shock differentially removed patients with more extensive damage and a greater potential for salvage from the subset of patients with anterior infarction. This is in part suggested by the smaller infarct size observed in patients with anterior infarction.
In conclusion, the results of the present study indicate that glyceryl trinitrate can be administered safely to patients with acute myocardial infarction without the use of invasive monitoring, provided that blood pressure and heart rate are monitored frequently and maintained within narrowly defined, preset limits. Our results indicate that glyceryl trinitrate reduces infarct size in patients with inferior infarction. 
